Gene · 7329
UBE2I: ubiquitin conjugating enzyme E2 I
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. UBE2I: ubiquitin conjugating enzyme E2 I. Genes, record 7329. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7329
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P63279 | SUMO-conjugating enzyme UBC9 | 158 | 33 | Ensembl, GeneID, HGNC |
Source UniProt
Patents113
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 69071 | P63279 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69072 | P63279 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69073 | P63279 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69074 | P63279 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69075 | P63279 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69076 | P63279 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5580 | P63279 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5580 | P63279 | Espacenet |
| WO 2024240908 A1 | 2024-11-28 | 38 | P63279 | Espacenet |
| US 12023385 B2 | 2024-07-02 | 37 | P63279 | Espacenet |
1 to 10 of 113
See all 113 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,903
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | UBE2I papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 16 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 13 | 2025 |
| U54CA118638 | 1/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership | 10 | 2025 |
| T32CA009110 | Training in Areas Fundamental to Cancer Research | 7 | 2025 |
| P01CA019014 | Viral Oncogenesis, Latency, and Replication | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 6 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 6 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 6 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 6 | 2025 |
1 to 10 of 1,903Source NIH's project files
See all 1,903 nih grantsPapers3,237
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Deconstructing the Alternative Lengthening of Telomeres: Integromics Prioritizes Five Master Hubs Dictating Clinical Survival and Therapeutic Vulnerabilities. | Biology (Basel) | 2026 | 42737963 | PubTator, text mining | PubMed |
| SelO functions as a tumor suppressor through AMPylating Cdk5rap3. | Proc Natl Acad Sci U S A | 2026 | 42735321 | PubTator, text mining | PubMed |
| SUMO1 modification stabilizes polymerase protein VP1 of Blotched Snakehead Virus. | Virology | 2026 | 42673726 | PubTator, text mining | PubMed |
| Pharmacological inhibition of the SUMOylation pathway: Mechanisms, inhibitors and therapeutic opportunities. | Pharmacol Res | 2026 | 42668077 | PubTator, text mining | PubMed |
| PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization. | J Exp Med | 2026 | 42663568 | PubTator, text mining | PubMed |
| Neurokinin-1 regulates progression of triple negative breast cancer by enhancing G3BP2 SUMOylation. | Cell Signal | 2026 | 42641840 | PubTator, text mining | PubMed |
| Tumor suppressor syntaxin binding protein 1 regulates alternative splicing of DNA repair genes related to radiation sensitivity in breast cancer cells. | Oncol Lett | 2026 | 42631023 | PubTator, text mining | PubMed |
| An Acetylation-Primed SUMOylation Switch Controls RORβ Stability through a p300-SIRT1 Regulatory Axis. | Res Sq | 2026 | 42539049 | PubTator, text mining | PubMed |
| UBC9 and PI3K Expression in Colorectal Cancer: Possible Prognostic Role. | APMIS | 2026 | 42522541 | PubTator, text mining | PubMed |
| CircRAD23B-208aa Promotes Gastric Cancer Progression by Activating the Unfolded Protein Response through PDIA5 SUMOylation. | Research (Wash D C) | 2026 | 42491210 | PubTator, text mining | PubMed |
1 to 10 of 3,237
See all 3,237 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7329
GET https://conductscience.org/api/genes/v1/7329/patents?page=2